https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Methohexital+AND+Sodium+AND+for+AND+Injection&limit=1&skip=0
Page 0 of 2
        "generic_name": [
          "METHOHEXITAL SODIUM"
        "brand_name": [
          "Brevital Sodium"
 
      "drug_interactions": [
        "Drug Interactions Prior chronic administration of barbiturates or phenytoin (e.g. for seizure disorder) appears to reduce the effectiveness of Brevital Sodium. Barbiturates may influence the metabolism of other concomitantly used drugs, such as phenytoin, halothane, anticoagulants, corticosteroids, ethyl alcohol, and propylene glycol-containing solutions."
      "adverse_reactions": [
        "ADVERSE REACTIONS Side effects associated with Brevital Sodium are extensions of pharmacologic effects and include: Cardiovascular—Circulatory depression, thrombophlebitis, hypotension, tachycardia, peripheral vascular collapse, and convulsions in association with cardiorespiratory arrest Respiratory—Respiratory depression (including apnea), cardiorespiratory arrest, laryngospasm, bronchospasm, hiccups, and dyspnea Neurologic—Skeletal muscle hyperactivity (twitching), injury to nerves adjacent to injection site, and seizures Psychiatric—Emergence delirium, restlessness, and anxiety may occur, especially in the presence of postoperative pain Gastrointestinal—Nausea, emesis, abdominal pain, and liver function tests abnormal Allergic—Erythema, pruritus, urticaria, and cases of anaphylaxis have been reported rarely Other—Other adverse reactions include pain at injection site, salivation, headache, and rhinitis For medical advice about adverse reactions contact your medical professional. To report SUSPECTED ADVERSE REACTIONS, contact JHP at 1-866-923-2547 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.fda.gov/medwatch/."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Methohexital+AND+Sodium+AND+for+AND+Injection&limit=1&skip=1
Page 1 of 2
        "generic_name": [
          "METHOHEXITAL SODIUM"
        "brand_name": [
          "Brevital Sodium"
 
      "drug_interactions": [
        "Drug Interactions Prior chronic administration of barbiturates or phenytoin (e.g. for seizure disorder) appears to reduce the effectiveness of Brevital Sodium. Barbiturates may influence the metabolism of other concomitantly used drugs, such as phenytoin, halothane, anticoagulants, corticosteroids, ethyl alcohol, and propylene glycol-containing solutions."
      "adverse_reactions": [
        "ADVERSE REACTIONS Side effects associated with Brevital Sodium are extensions of pharmacologic effects and include: Cardiovascular—Circulatory depression, thrombophlebitis, hypotension, tachycardia, peripheral vascular collapse, and convulsions in association with cardiorespiratory arrest Respiratory—Respiratory depression (including apnea), cardiorespiratory arrest, laryngospasm, bronchospasm, hiccups, and dyspnea Neurologic—Skeletal muscle hyperactivity (twitching), injury to nerves adjacent to injection site, and seizures Psychiatric—Emergence delirium, restlessness, and anxiety may occur, especially in the presence of postoperative pain Gastrointestinal—Nausea, emesis, abdominal pain, and liver function tests abnormal Allergic—Erythema, pruritus, urticaria, and cases of anaphylaxis have been reported rarely Other—Other adverse reactions include pain at injection site, salivation, headache, and rhinitis For medical advice about adverse reactions contact your medical professional. To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical, Inc. at 1-800-828-9393 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch/."
 
 
--------------------------------------------------------------------------------------------------------------------
